Sinovac
Sinovac at Glance
Our History
Company Culture
Corporate Social Responsibilities
News
Press Releases
Social Media
Image and Video Library
Products
Vaccines
Logistics Distribution
International Business
Product Consultation
Adverse reaction / event report
Innovation
R&D Platform
Pipeline Products
Scientific Achievements
Our Partners
Quality
QMS System
Quality Certification
Investor
Company Profile
Corporate Governance
Stock Information
Financial Reports
SEC Filings
Career
Our Talent
Join us
Sinovac academy
Mumps Vaccine, Live
Launched in 2012
lNo antibiotics added throughout the production process
lSeroconversion rate increased to 88.9% after 1 dose of the booster vaccine
